Using Mirabegron to Increase BP in Patients With POTS
Status:
Recruiting
Trial end date:
2026-11-21
Target enrollment:
Participant gender:
Summary
This is a pilot dose-finding study to test the hypothesis that mirabegron increases systolic
blood pressure (BP), prevents syncope/presyncope, and improves the quality of life (QOL),
functional capacity, chest pain, and overactive bladder (OAB) symptoms in patients with
postural orthostatic tachycardia syndrome (POTS) who have a documented history of hypotension
inadequately responsive to conventional treatments. The American Heart Association funds this
study.